Top Markets
#1 Derive Derive +36.07%
#2 Cross Cross +18.56%
#3 The Bitcoin Bull The Bitcoin Bull +14.92%
#4 Geodnet Geodnet +10.04%
#5 Gama Token Gama Token +9.18%
#6 Biconomy Biconomy +8.72%
#7 Starpower Starpower +7.90%
#8 Humanity Humanity +7.57%
#9 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +6.71%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +6.64%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
MetaVia Inc. MetaVia Inc.

MetaVia Inc.

MTVA
Rank in Stocks #35877
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Share Price
$1.51
Last synced: 2026-08-14
Market Cap
$3.32M
Change (1 day)
3.42%
Change (1 year)
-78.55%
Country
US
Trade MetaVia Inc. (MTVA)

Category

Healthcare
Revenue for MetaVia Inc. (MTVA)
Revenue in Aug 2026 TTM: 0
According to MetaVia Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for MetaVia Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE